ISRG · Insider Trading
Intuitive Surgical Inc.
Every open-market purchase and sale reported by ISRG officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-13 | Patricia L Wadors | SVP Chief Human Resources Offi | MIXED | +1,078 | −$450.25K |
| 2026-10-13 | Gary Loeb | EVP & Chief Legal and Complian | MIXED | +1,316 | −$549.45K |
| 2026-09-16 | Fredrik Widman | VP Corporate Controller | MIXED | — | −$304.83K |
| 2026-09-11 | Mark Brosius | EVP & Chief Mfg and Supply Cha | Sell | −48 | −$17.14K |
| 2026-09-09 | Mark Brosius | EVP & Chief Mfg and Supply Cha | Sell | −69 | −$24.67K |
| 2026-08-21 | Mark Brosius | EVP & Chief Mfg and Supply Cha | Sell | −154 | −$59.44K |
| 2026-08-19 | Mark Brosius | EVP & Chief Mfg and Supply Cha | Sell | −231 | −$90.78K |
| 2026-08-12 | Gary S Guthart | Director | Sell | −10,000 | −$4.00M |
| 2026-08-11 | Amy L Ladd | Director | Sell | −472 | −$179.90K |
| 2026-08-10 | Gary Loeb | EVP & Chief Legal and Complian | Sell | −400 | −$151.60K |
| 2026-07-31 | Mark Brosius | EVP & Chief Mfg and Supply Cha | Sell | −56 | −$19.54K |
| 2026-07-29 | Mark Brosius | EVP & Chief Mfg and Supply Cha | Sell | −84 | −$29.95K |
| 2026-07-13 | David J. Rosa | Chief Executive Officer (CEO) | MIXED | +963 | −$389.74K |
| 2026-06-12 | Mark Brosius | EVP & Chief Mfg and Supply Cha | Sell | −48 | −$19.83K |
| 2026-06-10 | Gary Loeb | EVP & Chief Legal and Complian | Sell | −400 | −$169.66K |
| 2026-06-10 | David J. Rosa | Chief Executive Officer (CEO) | MIXED | +684 | −$287.54K |
| 2026-06-10 | Mark Brosius | EVP & Chief Mfg and Supply Cha | Sell | −69 | −$29.10K |
| 2026-06-02 | Iman Jeddi | SVP & GM da Vinci Platforms & | MIXED | — | −$1.93M |
| 2026-05-22 | Mark Brosius | EVP & Chief Mfg and Supply Cha | Sell | −36 | −$15.95K |
| 2026-05-20 | Mark Brosius | EVP & Chief Mfg and Supply Cha | Sell | −54 | −$23.46K |
| 2026-05-11 | Gary Loeb | EVP & Chief Legal and Complian | Sell | −400 | −$178.78K |
| 2026-05-01 | Gary S Guthart | Director | A | +554 deriv. | — |
| 2026-04-30 | Craig H Barratt | Director | M | +750 | — |
| 2026-04-30 | Joseph C Beery | Director | M | +531 | — |
| 2026-04-30 | Lewis Chew | Director | M | +531 | — |
| 2026-04-30 | Amal M Johnson | Director | M | +531 | — |
| 2026-04-30 | Sreelakshmi Kolli | Director | M | +531 | — |
| 2026-04-30 | Amy L Ladd | Director | M | +531 | — |
| 2026-04-30 | Keith R Leonard | Director | M | +531 | — |
| 2026-04-30 | Jami K Nachtsheim | Director | M | +531 | — |
| 2026-04-30 | Monica P Reed | Director | M | +531 | — |
| 2026-04-29 | Amy L Ladd | Director | Sell | −619 | −$291.89K |
| 2026-03-11 | Myriam Curet | EVP & Chief Medical Officer | MIXED | — | −$27.78K |
| 2026-03-10 | Mark Brosius | SVP & Chief Mfg and Supply Cha | Sell | −1,293 | −$630.47K |
| 2026-03-05 | Mark Brosius | SVP & Chief Mfg and Supply Cha | Sell | −3,658 | −$1.82M |
| 2026-03-03 | Gary S Guthart | Director | MIXED | +14,538 | −$7.20M |
| 2026-03-03 | Iman Jeddi | SVP & GM da Vinci Platforms & | MIXED | +4,538 | −$2.25M |
| 2026-03-03 | Myriam Curet | EVP & Chief Medical Officer | MIXED | −4,728 | −$2.34M |
| 2026-03-03 | Fredrik Widman | VP Corporate Controller | MIXED | −132 | −$299.23K |
| 2026-03-02 | Myriam Curet | EVP & Chief Medical Officer | MIXED | +2,383 | −$3.51M |
| 2026-03-02 | Mark Brosius | SVP & Chief Mfg and Supply Cha | MIXED | +4,665 | −$2.31M |
| 2026-03-02 | David J. Rosa | Chief Executive Officer (CEO) | MIXED | +12,561 | −$6.22M |
| 2026-03-02 | Henry L Charlton | EVP & Chief Commercial and Mkt | MIXED | +6,390 | −$2.59M |
| 2026-03-02 | Gary Loeb | EVP & Chief Legal and Complian | MIXED | +1,586 | −$786.48K |
| 2026-03-02 | Jamie Samath | EVP & CFO & Enterprise Technol | MIXED | +5,809 | −$2.88M |
| 2026-02-27 | Mark Brosius | SVP & Chief Mfg and Supply Cha | MIXED | +1,307 | −$651.95K |
| 2026-02-27 | Gary S Guthart | Director | MIXED | +4,230 | −$2.11M |
| 2026-02-27 | David J. Rosa | Chief Executive Officer (CEO) | MIXED | +3,078 | −$1.53M |
| 2026-02-27 | Fredrik Widman | VP Corporate Controller | MIXED | +498 | −$248.53K |
| 2026-02-27 | Myriam Curet | EVP & Chief Medical Officer | MIXED | +2,345 | −$1.17M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Gary S Guthart | Director | 1,256,193 | $537.15M |
| David J. Rosa | Chief Executive Officer (CEO) | 247,803 | $105.96M |
| Iman Jeddi | SVP & GM da Vinci Platforms & | 38,737 | $16.56M |
| Craig H Barratt | Director | 28,698 | $12.27M |
| Jamie Samath | EVP & CFO & Enterprise Technol | 20,709 | $8.86M |
| Mark J Rubash | Director | 16,790 | $7.18M |
| Amal M Johnson | Director | 13,545 | $5.79M |
| Brian Edward Miller | EVP & Chief Digital Officer | 7,960 | $3.40M |
| Jami K Nachtsheim | Director | 6,902 | $2.95M |
| Gary Loeb | EVP & Chief Legal and Complian | 6,636 | $2.84M |
| Henry L Charlton | EVP & Chief Commercial and Mkt | 5,972 | $2.55M |
| Robert DeSantis | EVP & Chief Strategy & Corp Op | 5,224 | $2.23M |
| Joseph C Beery | Director | 3,641 | $1.56M |
| Monica P Reed | Director | 2,876 | $1.23M |
| Fredrik Widman | VP Corporate Controller | 1,572 | $672.20K |
| Sreelakshmi Kolli | Director | 1,510 | $645.68K |
| Lewis Chew | Director | 1,314 | $561.87K |
| Patricia L Wadors | SVP Chief Human Resources Offi | 1,078 | $460.96K |
| Keith R Leonard | Director | 901 | $385.27K |
| Mark Brosius | EVP & Chief Mfg and Supply Cha | 764 | $326.69K |
| Myriam Curet | EVP & Chief Medical Officer | 514 | $219.79K |
| Amy L Ladd | Director | 251 | $107.33K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ISRG quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.